Peptide Array for Profiling of Autoantibodies in Non-small Cell Lung Cancer
Small Business Information
20/20 GENESYSTEMS, INC., 9700 GREAT SENECA HWY, ROCKVILLE, MD, 20850
AbstractDESCRIPTION (provided by applicant): Approximately 135,000 new cases of non-small cell lung cancer (NSCLC) are diagnosed each year in the USA, yet only 20%-25% of those patients will be diagnosed at a sufficiently early stage to be cured by surgical or oth er procedures. When used in concert with radiographic imaging, a sensitive and specific blood test for NSCLC could be a clinically valuable and cost-effective tool for early diagnosis. The immune system responds to tumor-associated protein by secreting aut oantibodies long before metastasis occurs. Autoantibody profiling for this important group of circulating tumor markers in peripheral blood has lead us to the identification of appropriate target peptides. We have developed a panel of 21 short peptides whi ch were formatted as a protein microarray for use in a simple capture immunoassay. When probed with a blood sample the array can identify the presence of tumor-associated antibodies in NSCLC but not in normals with both sensitivity and a specificity exceed ing 90% at early and later stages of the disease. As used to measure tumor-associated antibodies in serum from a cohort of cancer patients and risk-matched controls, this test affords predictive accuracy that exceeds that of currently available circulating NSCLC- associated protein markers. The overall purpose of this application is to prepare microarrays of a panel of peptide targets and to demonstrate that they enable measurement of autoantibody profiles that can distinguish cancer from normal blood sampl es with unprecedented sensitivity and specificity. Microarrays of the purified peptides will be used for rigorous optimization and standardization of all technical and clinical performance measures for the multi-target immunoassay. Our initial clinical app lication will be early detection of lung cancer, although multiple applications in lung cancer management are rational. Our data shows feasibility and proof of concept that supports the rationale for further development and testing of this approach. A subs equent Phase II application will lead to use of an appropriate platform for definitive marker validation trials for application to clinical screening of NSCLC. Thus the primary goal of this application is to develop a novel blood test for NSCLC that can be rapidly translated into clinical practice. A blood test for early detection of lung cancer could provide a cost-effective screening approach, and in concert with CT scanning would enable a viable strategy for reducing the severe mortality rate of this dis ease.
* information listed above is at the time of submission.